ZEO ScientifiX expands Medical Advisory Board
Analysis based on 6 articles · First reported Jun 09, 2026 · Last updated Jun 09, 2026
The expansion of ZEO ScientifiX's Medical Advisory Board is likely to be viewed positively by the market, as it strengthens the company's scientific credibility and leadership in the growing field of regenerative medicine. This could lead to increased investor confidence and potentially a positive impact on ZEO ScientifiX's stock price.
ZEO ScientifiX, a biologics research and products company, announced the expansion of its Medical Advisory Board with the addition of nine highly-recognized physicians and scientific innovators. These new members bring expertise across various disciplines including orthopedics, oncology, longevity science, pain management, plastic surgery, and advanced biologic therapies. The expanded board aims to deepen ZEO ScientifiX's scientific foundation, advance clinical innovation, and enhance physician education in regenerative medicine. Key new members include Elizabeth Parrish, a pioneer in gene-based longevity biotechnology, and Mark A. Rosenberg, president of Advanced Medical Therapeutics. George C. Shapiro, ZEO ScientifiX's Chief Medical Officer, chairs the board, emphasizing the company's commitment to understanding and influencing biological systems related to aging.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard